Antibody-drug conjugates (ADCs) have emerged as highly effective targeted therapies, especially in cancer treatment. Recent breakthroughs in combining antibodies with potent cytotoxic drugs have revolutionized treatment delivery.
Join STAT and Samsung for this virtual event on May 29th at 1 p.m. EDT as we explore the critical role of contract development and manufacturing organizations (CDMOs) in ensuring the successful and safe manufacturing of ADCs, incorporating enhanced facility design.
.jpg?noresize&width=1200&upscale=true&name=SBS_Samsung_TallEmail%20(3).jpg)
No comments